NO332126B1 - Pyrido[2,1-a]isokinolinderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse i medikamenter samt slike forbindelser for anvendelse i behandling av sykdom - Google Patents
Pyrido[2,1-a]isokinolinderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse i medikamenter samt slike forbindelser for anvendelse i behandling av sykdom Download PDFInfo
- Publication number
- NO332126B1 NO332126B1 NO20055887A NO20055887A NO332126B1 NO 332126 B1 NO332126 B1 NO 332126B1 NO 20055887 A NO20055887 A NO 20055887A NO 20055887 A NO20055887 A NO 20055887A NO 332126 B1 NO332126 B1 NO 332126B1
- Authority
- NO
- Norway
- Prior art keywords
- pyrido
- hexahydro
- dimethoxy
- amino
- isoquinolin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 152
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 201000010099 disease Diseases 0.000 title claims abstract description 7
- SSSYOIPHXANRMO-UHFFFAOYSA-N 4h-benzo[a]quinolizine Chemical class C1=CC=C2C3=CC=CCN3C=CC2=C1 SSSYOIPHXANRMO-UHFFFAOYSA-N 0.000 title abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 thiazolidin-3-yl Chemical group 0.000 claims description 33
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 19
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- NUBNLQCQSWLNCX-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-4-methylpyrrolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(C)CC1=O NUBNLQCQSWLNCX-UHFFFAOYSA-N 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- GUYMHFIHHOEFOA-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-4-(fluoromethyl)pyrrolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(CF)CC1=O GUYMHFIHHOEFOA-UHFFFAOYSA-N 0.000 claims description 12
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- OXRRHYRRQWIHIV-UHFFFAOYSA-N 2,3-dihydro-1h-pyridin-6-one Chemical compound O=C1NCCC=C1 OXRRHYRRQWIHIV-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- HVZDVNGFZKXGRM-UHFFFAOYSA-N (2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-(1,3-thiazolidin-3-yl)methanone Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1C(=O)N1CCSC1 HVZDVNGFZKXGRM-UHFFFAOYSA-N 0.000 claims description 6
- ZFIBBFIUTCQDQR-ULQDDVLXSA-N (2s,3s,11bs)-3-(1,1-dioxothiazinan-2-yl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-amine Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)CCCCS1(=O)=O ZFIBBFIUTCQDQR-ULQDDVLXSA-N 0.000 claims description 6
- NUBNLQCQSWLNCX-ZCPGHIKRSA-N (4r)-1-[(2s,3s,11bs)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]-4-methylpyrrolidin-2-one Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@H](C)CC1=O NUBNLQCQSWLNCX-ZCPGHIKRSA-N 0.000 claims description 6
- NUBNLQCQSWLNCX-STECZYCISA-N (4s)-1-[(2s,3s,11bs)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]-4-methylpyrrolidin-2-one Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@@H](C)CC1=O NUBNLQCQSWLNCX-STECZYCISA-N 0.000 claims description 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 6
- YRRZMQVMDNBBLU-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-2,3-dihydropyridin-6-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCC=CC1=O YRRZMQVMDNBBLU-UHFFFAOYSA-N 0.000 claims description 6
- DMHQAAKROHVXNB-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-5-methylpiperidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(C)CCC1=O DMHQAAKROHVXNB-UHFFFAOYSA-N 0.000 claims description 6
- WXDAFCAAWAJFAG-UHFFFAOYSA-N 3-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-5-methyl-1,3-oxazolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(C)OC1=O WXDAFCAAWAJFAG-UHFFFAOYSA-N 0.000 claims description 6
- GUYMHFIHHOEFOA-ZCPGHIKRSA-N Carmegliptin Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@@H](CF)CC1=O GUYMHFIHHOEFOA-ZCPGHIKRSA-N 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- QSVZHKOHWFGXHF-ULQDDVLXSA-N 1-[(2s,3s,11bs)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]piperidin-2-one Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)CCCCC1=O QSVZHKOHWFGXHF-ULQDDVLXSA-N 0.000 claims description 5
- ZFIBBFIUTCQDQR-UHFFFAOYSA-N 3-(1,1-dioxothiazinan-2-yl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-amine Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCCS1(=O)=O ZFIBBFIUTCQDQR-UHFFFAOYSA-N 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 230000006806 disease prevention Effects 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- NWFBJRXBWCRZHR-UHFFFAOYSA-N (2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-pyrrolidin-1-ylmethanone Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1C(=O)N1CCCC1 NWFBJRXBWCRZHR-UHFFFAOYSA-N 0.000 claims description 4
- GUYMHFIHHOEFOA-STECZYCISA-N (4r)-1-[(2s,3s,11bs)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@H](CF)CC1=O GUYMHFIHHOEFOA-STECZYCISA-N 0.000 claims description 4
- NUBNLQCQSWLNCX-WBQNTZJQSA-N (4s)-1-[(2r,3r,11br)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]-4-methylpyrrolidin-2-one Chemical compound N1([C@@H]2CN3CCC=4C=C(C(=CC=4[C@H]3C[C@H]2N)OC)OC)C[C@@H](C)CC1=O NUBNLQCQSWLNCX-WBQNTZJQSA-N 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- RRMHXFUPTNJEEM-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-4-ethylpyrrolidin-2-one Chemical compound O=C1CC(CC)CN1C1C(N)CC2C3=CC(OC)=C(OC)C=C3CCN2C1 RRMHXFUPTNJEEM-UHFFFAOYSA-N 0.000 claims description 4
- HNCSYKUUKHXRCJ-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)azepan-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCCCC1=O HNCSYKUUKHXRCJ-UHFFFAOYSA-N 0.000 claims description 4
- QSVZHKOHWFGXHF-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)piperidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCCC1=O QSVZHKOHWFGXHF-UHFFFAOYSA-N 0.000 claims description 4
- QSVZHKOHWFGXHF-BRWVUGGUSA-N 1-[(2r,3r,11br)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]piperidin-2-one Chemical compound N1([C@@H]2CN3CCC=4C=C(C(=CC=4[C@H]3C[C@H]2N)OC)OC)CCCCC1=O QSVZHKOHWFGXHF-BRWVUGGUSA-N 0.000 claims description 4
- CCTPKHROVIWMRG-UHFFFAOYSA-N 3-(1,1-dioxo-1,2-thiazolidin-2-yl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-amine Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCS1(=O)=O CCTPKHROVIWMRG-UHFFFAOYSA-N 0.000 claims description 4
- NSDPVRNHTOFONC-UHFFFAOYSA-N 3-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-1,3-oxazinan-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCOC1=O NSDPVRNHTOFONC-UHFFFAOYSA-N 0.000 claims description 4
- QFENECDXQMZEDF-UHFFFAOYSA-N 3-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-5-(fluoromethyl)-1,3-oxazolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(CF)OC1=O QFENECDXQMZEDF-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- BPBNQPDORGSCJP-UHFFFAOYSA-N n-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)propanamide Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(NC(=O)CC)C(N)C2 BPBNQPDORGSCJP-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Chemical group 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- IDVRYJZZCUBUJS-UHFFFAOYSA-N (2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-(azetidin-1-yl)methanone Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1C(=O)N1CCC1 IDVRYJZZCUBUJS-UHFFFAOYSA-N 0.000 claims description 3
- INWWWTILZXHHJN-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)pyrrolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCC1=O INWWWTILZXHHJN-UHFFFAOYSA-N 0.000 claims description 3
- YRKRGYRYEQYTOH-UHFFFAOYSA-N 4-methylpyrrolidin-2-one Chemical compound CC1CNC(=O)C1 YRKRGYRYEQYTOH-UHFFFAOYSA-N 0.000 claims description 3
- HBRXQSHUXIJOKV-UHFFFAOYSA-N 5-methyl-1,3-oxazolidin-2-one Chemical compound CC1CNC(=O)O1 HBRXQSHUXIJOKV-UHFFFAOYSA-N 0.000 claims description 3
- NSRPFJGOCZUUHE-UHFFFAOYSA-N 5-methylpiperidin-2-one Chemical compound CC1CCC(=O)NC1 NSRPFJGOCZUUHE-UHFFFAOYSA-N 0.000 claims description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
- RZLRUIOODAEHEX-UHFFFAOYSA-N n-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)butanamide Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(NC(=O)CCC)C(N)C2 RZLRUIOODAEHEX-UHFFFAOYSA-N 0.000 claims description 3
- IYFPXHSCQNVJEU-UHFFFAOYSA-N n-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)cyclopropanecarboxamide Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1NC(=O)C1CC1 IYFPXHSCQNVJEU-UHFFFAOYSA-N 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- OYELEBBISJGNHJ-UHFFFAOYSA-N 1,3-oxazinan-2-one Chemical compound O=C1NCCCO1 OYELEBBISJGNHJ-UHFFFAOYSA-N 0.000 claims description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- KDYHKCSEXBPFCA-UHFFFAOYSA-N 3-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-1,3-oxazolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCOC1=O KDYHKCSEXBPFCA-UHFFFAOYSA-N 0.000 claims description 2
- AOCWQPKHSMJWPL-UHFFFAOYSA-N 3-methylpyrrolidin-2-one Chemical compound CC1CCNC1=O AOCWQPKHSMJWPL-UHFFFAOYSA-N 0.000 claims description 2
- ZBCUGJNJBOSHIA-UHFFFAOYSA-N 4-ethylpyrrolidin-2-one Chemical compound CCC1CNC(=O)C1 ZBCUGJNJBOSHIA-UHFFFAOYSA-N 0.000 claims description 2
- WKBDRRWUJFWHFP-UHFFFAOYSA-N 4-fluoro-1-methylpyrrolidin-2-one Chemical compound CN1CC(F)CC1=O WKBDRRWUJFWHFP-UHFFFAOYSA-N 0.000 claims description 2
- PTSGHGGLRADEFP-UHFFFAOYSA-N 4-methylpiperidin-2-one Chemical compound CC1CCNC(=O)C1 PTSGHGGLRADEFP-UHFFFAOYSA-N 0.000 claims description 2
- KMVXQRLMTSRFBF-UHFFFAOYSA-N 5-(fluoromethyl)-1,3-oxazolidin-2-one Chemical compound FCC1CNC(=O)O1 KMVXQRLMTSRFBF-UHFFFAOYSA-N 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 2
- YVIVRJLWYJGJTJ-UHFFFAOYSA-N gamma-Valerolactam Chemical compound CC1CCC(=O)N1 YVIVRJLWYJGJTJ-UHFFFAOYSA-N 0.000 claims description 2
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 238000007429 general method Methods 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 40
- UIRKISQHYDALJC-UHFFFAOYSA-N tert-butyl n-(3-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl)carbamate Chemical compound C1CN2CC(N)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 UIRKISQHYDALJC-UHFFFAOYSA-N 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 229910004298 SiO 2 Inorganic materials 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 239000000460 chlorine Substances 0.000 description 17
- 239000006260 foam Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000004587 chromatography analysis Methods 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 239000012267 brine Substances 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000012876 carrier material Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- ANIRIAKHAXVJDD-UHFFFAOYSA-N 9,10-dimethoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine-3-carboxylic acid Chemical compound C1CN2CC(C(O)=O)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 ANIRIAKHAXVJDD-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 102000045598 human DPP4 Human genes 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- ZKBIZSYATOJUSX-KNTRFNDTSA-N tert-butyl n-[(2s,3s,11bs)-3-[(4r)-4-(fluoromethyl)-2-oxopyrrolidin-1-yl]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2NC(=O)OC(C)(C)C)OC)OC)C[C@H](CF)CC1=O ZKBIZSYATOJUSX-KNTRFNDTSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- NUBNLQCQSWLNCX-BASLNEPJSA-N (4r)-1-[(2r,3r,11br)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]-4-methylpyrrolidin-2-one Chemical compound N1([C@@H]2CN3CCC=4C=C(C(=CC=4[C@H]3C[C@H]2N)OC)OC)C[C@H](C)CC1=O NUBNLQCQSWLNCX-BASLNEPJSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WVBKPWPUNZOWNG-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-4-methylpiperidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCC(C)CC1=O WVBKPWPUNZOWNG-UHFFFAOYSA-N 0.000 description 3
- XPJQIDXNDRRUFW-UHFFFAOYSA-N 3-(chloromethyl)-4-fluorobutanoyl chloride Chemical compound FCC(CCl)CC(Cl)=O XPJQIDXNDRRUFW-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- KJLKBWRENGBSKF-UHFFFAOYSA-N ethyl 2-amino-9,10-dimethoxy-4,6,7,11b-tetrahydro-1h-benzo[a]quinolizine-3-carboxylate Chemical compound COC1=C(OC)C=C2C3CC(N)=C(C(=O)OCC)CN3CCC2=C1 KJLKBWRENGBSKF-UHFFFAOYSA-N 0.000 description 3
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 3
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- OUQVKRKGTAUJQA-UHFFFAOYSA-N n-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine Chemical compound C1=CC=CC2=C(O)C(C(=O)NCC(=O)O)=NC(Cl)=C21 OUQVKRKGTAUJQA-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- UIRKISQHYDALJC-JYJNAYRXSA-N tert-butyl n-[(2s,3s,11bs)-3-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2C[C@H](N)[C@@H](NC(=O)OC(C)(C)C)C[C@H]2C2=C1C=C(OC)C(OC)=C2 UIRKISQHYDALJC-JYJNAYRXSA-N 0.000 description 3
- KCLHLZWWNGHCID-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(2-oxopiperidin-1-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCCC1=O KCLHLZWWNGHCID-UHFFFAOYSA-N 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical group [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DDKJYXSAKVWFLS-PECAVBAFSA-N (4r)-1-[(2s,3s,11bs)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@H](CF)CC1=O DDKJYXSAKVWFLS-PECAVBAFSA-N 0.000 description 2
- DDKJYXSAKVWFLS-LSKWAPIISA-N (4s)-1-[(2s,3s,11bs)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one;dihydrochloride Chemical compound Cl.Cl.N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@@H](CF)CC1=O DDKJYXSAKVWFLS-LSKWAPIISA-N 0.000 description 2
- UORKUFQLSBYWNL-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-3-methylpyrrolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCC(C)C1=O UORKUFQLSBYWNL-UHFFFAOYSA-N 0.000 description 2
- ARQNYGOILDZRGJ-UHFFFAOYSA-N 1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl)-5-methylpyrrolidin-2-one Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1C(C)CCC1=O ARQNYGOILDZRGJ-UHFFFAOYSA-N 0.000 description 2
- KBXXMRIAELGZJZ-UHFFFAOYSA-N 1-[2-(benzylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-3-yl]azepan-2-one Chemical compound C1C2C=3C=C(OC)C(OC)=CC=3CCN2CC(N2C(CCCCC2)=O)C1NCC1=CC=CC=C1 KBXXMRIAELGZJZ-UHFFFAOYSA-N 0.000 description 2
- AVMHMVJVHYGDOO-UHFFFAOYSA-N 1-bromobut-2-ene Chemical compound CC=CCBr AVMHMVJVHYGDOO-UHFFFAOYSA-N 0.000 description 2
- SNOBQHSFTVYKRO-UHFFFAOYSA-N 4-(fluoromethyl)oxolan-2-one Chemical compound FCC1COC(=O)C1 SNOBQHSFTVYKRO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- LJXFUBMDMUVZKA-UHFFFAOYSA-N 4-chloro-2-methylbutanoyl chloride Chemical compound ClC(=O)C(C)CCCl LJXFUBMDMUVZKA-UHFFFAOYSA-N 0.000 description 2
- HCBIDLRKPXILPU-UHFFFAOYSA-N 4-chloropentanoyl chloride Chemical compound CC(Cl)CCC(Cl)=O HCBIDLRKPXILPU-UHFFFAOYSA-N 0.000 description 2
- OFOCHMIQWVHCGE-UHFFFAOYSA-N 5-chloro-4-methylpentanoyl chloride Chemical compound ClCC(C)CCC(Cl)=O OFOCHMIQWVHCGE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004129 EU approved improving agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- ZRWJUYAPBWQOIH-UHFFFAOYSA-N ethyl 2-(benzylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine-3-carboxylate Chemical compound CCOC(=O)C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1NCC1=CC=CC=C1 ZRWJUYAPBWQOIH-UHFFFAOYSA-N 0.000 description 2
- RLUWHGCQILMZMC-LBPRGKRZSA-N ethyl 2-[(1s)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]acetate Chemical compound COC1=C(OC)C=C2[C@H](CC(=O)OCC)NCCC2=C1 RLUWHGCQILMZMC-LBPRGKRZSA-N 0.000 description 2
- XIRIKQKWAFNOGD-UHFFFAOYSA-N ethyl 2-[benzyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine-3-carboxylate Chemical compound CCOC(=O)C1CN2CCC3=CC(OC)=C(OC)C=C3C2CC1N(C(=O)OC(C)(C)C)CC1=CC=CC=C1 XIRIKQKWAFNOGD-UHFFFAOYSA-N 0.000 description 2
- WTWJEJFVUQNVLB-UHFFFAOYSA-N ethyl 9,10-dimethoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine-3-carboxylate Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(C(=O)OCC)C(NC(=O)OC(C)(C)C)C2 WTWJEJFVUQNVLB-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- GAEKPEKOJKCEMS-UHFFFAOYSA-N gamma-valerolactone Chemical compound CC1CCC(=O)O1 GAEKPEKOJKCEMS-UHFFFAOYSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VKAUJRJDFLNGGC-UHFFFAOYSA-N tert-butyl n-(3-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl)-n-benzylcarbamate Chemical compound C1C2C=3C=C(OC)C(OC)=CC=3CCN2CC(N)C1N(C(=O)OC(C)(C)C)CC1=CC=CC=C1 VKAUJRJDFLNGGC-UHFFFAOYSA-N 0.000 description 2
- ZKBIZSYATOJUSX-TTYHFUOFSA-N tert-butyl n-[(2s,3s,11bs)-3-[(4s)-4-(fluoromethyl)-2-oxopyrrolidin-1-yl]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2NC(=O)OC(C)(C)C)OC)OC)C[C@@H](CF)CC1=O ZKBIZSYATOJUSX-TTYHFUOFSA-N 0.000 description 2
- UGDXUXWRSOGSCM-UHFFFAOYSA-N tert-butyl n-[3-(1,1-dioxo-1,2-thiazolidin-2-yl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCS1(=O)=O UGDXUXWRSOGSCM-UHFFFAOYSA-N 0.000 description 2
- BZBIFHHTERJZHD-UHFFFAOYSA-N tert-butyl n-[3-(1,1-dioxothiazinan-2-yl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCCS1(=O)=O BZBIFHHTERJZHD-UHFFFAOYSA-N 0.000 description 2
- LZCCKJHCWMGIHE-UHFFFAOYSA-N tert-butyl n-[3-(4-chlorobutanoylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)CCCCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 LZCCKJHCWMGIHE-UHFFFAOYSA-N 0.000 description 2
- VYHPZLTXSDPFFC-UHFFFAOYSA-N tert-butyl n-[3-(4-chloropentanoylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)CCC(C)Cl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 VYHPZLTXSDPFFC-UHFFFAOYSA-N 0.000 description 2
- AXYXNMFPQICZRP-UHFFFAOYSA-N tert-butyl n-[3-(4-ethyl-2-oxopyrrolidin-1-yl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound O=C1CC(CC)CN1C1C(NC(=O)OC(C)(C)C)CC2C3=CC(OC)=C(OC)C=C3CCN2C1 AXYXNMFPQICZRP-UHFFFAOYSA-N 0.000 description 2
- VBCXLVHCWOXTES-UHFFFAOYSA-N tert-butyl n-[3-(5-chloropentanoylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)CCCCCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 VBCXLVHCWOXTES-UHFFFAOYSA-N 0.000 description 2
- YSEQBHRZPUGERX-UHFFFAOYSA-N tert-butyl n-[3-(but-3-enylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NCCC=C)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 YSEQBHRZPUGERX-UHFFFAOYSA-N 0.000 description 2
- OOURTHLVHMGLAL-UHFFFAOYSA-N tert-butyl n-[3-[(1-chloro-3-fluoropropan-2-yl)oxycarbonylamino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)OC(CF)CCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 OOURTHLVHMGLAL-UHFFFAOYSA-N 0.000 description 2
- PGCHMJWIDLEDHC-UHFFFAOYSA-N tert-butyl n-[3-[(4-chloro-3-methylbutanoyl)amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)CC(C)CCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 PGCHMJWIDLEDHC-UHFFFAOYSA-N 0.000 description 2
- DWBSVQRAZRGUMU-UHFFFAOYSA-N tert-butyl n-[3-[(5-chloro-3-methylpentanoyl)amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)CC(C)CCCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 DWBSVQRAZRGUMU-UHFFFAOYSA-N 0.000 description 2
- KBVAZAHDXOJRCC-UHFFFAOYSA-N tert-butyl n-[3-[(5-chloro-4-methylpentanoyl)amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)CCC(C)CCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 KBVAZAHDXOJRCC-UHFFFAOYSA-N 0.000 description 2
- BSRSRFUNJYGNMK-UHFFFAOYSA-N tert-butyl n-[3-[3-(chloromethyl)pentanoylamino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(NC(=O)CC(CCl)CC)C(NC(=O)OC(C)(C)C)C2 BSRSRFUNJYGNMK-UHFFFAOYSA-N 0.000 description 2
- VRPRRGNPLUDQOP-UHFFFAOYSA-N tert-butyl n-[3-[5-(fluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(CF)OC1=O VRPRRGNPLUDQOP-UHFFFAOYSA-N 0.000 description 2
- OIHFMKDLZUJYSM-UHFFFAOYSA-N tert-butyl n-[3-[[3-(chloromethyl)-4-fluorobutanoyl]amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)CC(CF)CCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 OIHFMKDLZUJYSM-UHFFFAOYSA-N 0.000 description 2
- ZPJFMNFCFAGYJG-UHFFFAOYSA-N tert-butyl n-[3-[but-3-enyl(prop-2-enoyl)amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(N(CCC=C)C(=O)C=C)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 ZPJFMNFCFAGYJG-UHFFFAOYSA-N 0.000 description 2
- UYYKRXYAWIWFDO-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(1,3-thiazolidine-3-carbonyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1C(=O)N1CCSC1 UYYKRXYAWIWFDO-UHFFFAOYSA-N 0.000 description 2
- NXYFITMMECCMEH-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(2-oxo-1,3-oxazinan-3-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCOC1=O NXYFITMMECCMEH-UHFFFAOYSA-N 0.000 description 2
- IXSNTDZBPHADSL-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(2-oxopyrrolidin-1-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCCC1=O IXSNTDZBPHADSL-UHFFFAOYSA-N 0.000 description 2
- WGQYGIGNQGZYKQ-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(4-methyl-2-oxopiperidin-1-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCC(C)CC1=O WGQYGIGNQGZYKQ-UHFFFAOYSA-N 0.000 description 2
- OMTKCHDJYCNWIR-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(4-methyl-2-oxopyrrolidin-1-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(C)CC1=O OMTKCHDJYCNWIR-UHFFFAOYSA-N 0.000 description 2
- YVVJVIIUXPOVTO-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(5-methyl-2-oxo-1,3-oxazolidin-3-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(C)OC1=O YVVJVIIUXPOVTO-UHFFFAOYSA-N 0.000 description 2
- ZTZJSXAMOSLHHY-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(5-methyl-2-oxopiperidin-1-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(C)CCC1=O ZTZJSXAMOSLHHY-UHFFFAOYSA-N 0.000 description 2
- AFPLICIVHRUFHI-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(6-oxo-2,3-dihydropyridin-1-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CCC=CC1=O AFPLICIVHRUFHI-UHFFFAOYSA-N 0.000 description 2
- PBZNMQTZSRMONF-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(propanoylamino)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(NC(=O)CC)C(NC(=O)OC(C)(C)C)C2 PBZNMQTZSRMONF-UHFFFAOYSA-N 0.000 description 2
- CAGBQPRAFZRXIE-UHFFFAOYSA-N tert-butyl n-[9,10-dimethoxy-3-(pyrrolidine-1-carbonyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1C(=O)N1CCCC1 CAGBQPRAFZRXIE-UHFFFAOYSA-N 0.000 description 2
- UVGPZRFQZDMPQD-UHFFFAOYSA-N tert-butyl n-benzyl-n-[3-(6-chlorohexanoylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1C2C=3C=C(OC)C(OC)=CC=3CCN2CC(NC(=O)CCCCCCl)C1N(C(=O)OC(C)(C)C)CC1=CC=CC=C1 UVGPZRFQZDMPQD-UHFFFAOYSA-N 0.000 description 2
- KLNMGKWFYSPCDU-UHFFFAOYSA-N tert-butyl n-benzyl-n-[9,10-dimethoxy-3-(2-oxoazepan-1-yl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1C2C=3C=C(OC)C(OC)=CC=3CCN2CC(N2C(CCCCC2)=O)C1N(C(=O)OC(C)(C)C)CC1=CC=CC=C1 KLNMGKWFYSPCDU-UHFFFAOYSA-N 0.000 description 2
- SEFKFZGZZMOJEG-UHFFFAOYSA-N tert-butyl n-benzyl-n-[9,10-dimethoxy-3-(phenylmethoxycarbonylamino)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C=1C=CC=CC=1CN(C(=O)OC(C)(C)C)C1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1NC(=O)OCC1=CC=CC=C1 SEFKFZGZZMOJEG-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OUNVPOVPWMNYPC-BMWKDGKBSA-N (2s)-1-(2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine-3-carbonyl)pyrrolidine-2-carbonitrile Chemical compound NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1C(=O)N1CCC[C@H]1C#N OUNVPOVPWMNYPC-BMWKDGKBSA-N 0.000 description 1
- WUOZBACYMYYTOQ-CABZTGNLSA-N (2s)-1-[(2s)-2-aminopropanoyl]-n-(4-nitrophenyl)pyrrolidine-2-carboxamide Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 WUOZBACYMYYTOQ-CABZTGNLSA-N 0.000 description 1
- ALSCEGDXFJIYES-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbonitrile Chemical compound N#C[C@@H]1CCCN1 ALSCEGDXFJIYES-YFKPBYRVSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- ZNKJYZHZWALQNX-UHFFFAOYSA-N 1-chloro-3-fluoropropan-2-ol Chemical compound FCC(O)CCl ZNKJYZHZWALQNX-UHFFFAOYSA-N 0.000 description 1
- YYTSGNJTASLUOY-UHFFFAOYSA-N 1-chloropropan-2-ol Chemical compound CC(O)CCl YYTSGNJTASLUOY-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SVDDJQGVOFZBNX-UHFFFAOYSA-N 2-chloroethyl carbonochloridate Chemical compound ClCCOC(Cl)=O SVDDJQGVOFZBNX-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- ZNGINKJHQQQORD-UHFFFAOYSA-N 2-trimethylsilylethanol Chemical compound C[Si](C)(C)CCO ZNGINKJHQQQORD-UHFFFAOYSA-N 0.000 description 1
- QDJCDUNKEPYSJQ-UHFFFAOYSA-N 3-(chloromethyl)pentanoyl chloride Chemical compound CCC(CCl)CC(Cl)=O QDJCDUNKEPYSJQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GPKDGVXBXQTHRY-UHFFFAOYSA-N 3-chloropropane-1-sulfonyl chloride Chemical compound ClCCCS(Cl)(=O)=O GPKDGVXBXQTHRY-UHFFFAOYSA-N 0.000 description 1
- MTXMEFUEBCFWCY-UHFFFAOYSA-N 3-chloropropyl carbonochloridate Chemical compound ClCCCOC(Cl)=O MTXMEFUEBCFWCY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CCPSECFWEJAIJD-UHFFFAOYSA-N 4-(fluoromethyl)pyrrolidin-2-one Chemical compound FCC1CNC(=O)C1 CCPSECFWEJAIJD-UHFFFAOYSA-N 0.000 description 1
- PVQRPRXBBGDUMX-UHFFFAOYSA-N 4-(hydroxymethyl)oxolan-2-one Chemical compound OCC1COC(=O)C1 PVQRPRXBBGDUMX-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- WPJSMHMSPFVCED-UHFFFAOYSA-N 4-chloro-3-methylbutanoyl chloride Chemical compound ClCC(C)CC(Cl)=O WPJSMHMSPFVCED-UHFFFAOYSA-N 0.000 description 1
- YDSCNYYRPIFOJD-UHFFFAOYSA-N 4-chlorobutane-1-sulfonyl chloride Chemical compound ClCCCCS(Cl)(=O)=O YDSCNYYRPIFOJD-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- KBOGMBQWZCIHNQ-UHFFFAOYSA-N 5-chloro-3-methylpentanoyl chloride Chemical compound ClCCC(C)CC(Cl)=O KBOGMBQWZCIHNQ-UHFFFAOYSA-N 0.000 description 1
- SVNNWKWHLOJLOK-UHFFFAOYSA-N 5-chloropentanoyl chloride Chemical compound ClCCCCC(Cl)=O SVNNWKWHLOJLOK-UHFFFAOYSA-N 0.000 description 1
- GQUBDAOKWZLWDI-UHFFFAOYSA-N 5-methyloxan-2-one Chemical compound CC1CCC(=O)OC1 GQUBDAOKWZLWDI-UHFFFAOYSA-N 0.000 description 1
- WZILXAPNPKMOSA-UHFFFAOYSA-N 6-chlorohexanoyl chloride Chemical compound ClCCCCCC(Cl)=O WZILXAPNPKMOSA-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- RLUWHGCQILMZMC-UHFFFAOYSA-N ethyl 2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)acetate Chemical compound COC1=C(OC)C=C2C(CC(=O)OCC)NCCC2=C1 RLUWHGCQILMZMC-UHFFFAOYSA-N 0.000 description 1
- NWALBPCIRJBNQZ-UHFFFAOYSA-N ethyl 9,10-dimethoxy-2-oxo-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizine-3-carboxylate Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(C(=O)OCC)C(=O)C2 NWALBPCIRJBNQZ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- RRIWSQXXBIFKQM-UHFFFAOYSA-M n-benzylcarbamate Chemical compound [O-]C(=O)NCC1=CC=CC=C1 RRIWSQXXBIFKQM-UHFFFAOYSA-M 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OIHFMKDLZUJYSM-FBOXXWIASA-N tert-butyl n-[(2s,3s,11bs)-3-[[3-(chloromethyl)-4-fluorobutanoyl]amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2C[C@H](NC(=O)CC(CF)CCl)[C@@H](NC(=O)OC(C)(C)C)C[C@H]2C2=C1C=C(OC)C(OC)=C2 OIHFMKDLZUJYSM-FBOXXWIASA-N 0.000 description 1
- MXAUOPDHXZPKTJ-UHFFFAOYSA-N tert-butyl n-[3-(3-chloropropylsulfonylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NS(=O)(=O)CCCCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 MXAUOPDHXZPKTJ-UHFFFAOYSA-N 0.000 description 1
- BLVYKFSDBDCXAZ-UHFFFAOYSA-N tert-butyl n-[3-(4-chlorobutylsulfonylamino)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NS(=O)(=O)CCCCCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 BLVYKFSDBDCXAZ-UHFFFAOYSA-N 0.000 description 1
- MMIANWVQVKRTCG-UHFFFAOYSA-N tert-butyl n-[3-(azetidine-1-carbonyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1C(=O)N1CCC1 MMIANWVQVKRTCG-UHFFFAOYSA-N 0.000 description 1
- ZISVOYFMMQXBFD-UHFFFAOYSA-N tert-butyl n-[3-[(4-chloro-2-methylbutanoyl)amino]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound C1CN2CC(NC(=O)C(C)CCCl)C(NC(=O)OC(C)(C)C)CC2C2=C1C=C(OC)C(OC)=C2 ZISVOYFMMQXBFD-UHFFFAOYSA-N 0.000 description 1
- ZKBIZSYATOJUSX-UHFFFAOYSA-N tert-butyl n-[3-[4-(fluoromethyl)-2-oxopyrrolidin-1-yl]-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CC2C=3C=C(OC)C(OC)=CC=3CCN2CC1N1CC(CF)CC1=O ZKBIZSYATOJUSX-UHFFFAOYSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03013404 | 2003-06-20 | ||
| PCT/EP2004/006355 WO2005000848A1 (en) | 2003-06-20 | 2004-06-11 | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20055887L NO20055887L (no) | 2006-01-19 |
| NO332126B1 true NO332126B1 (no) | 2012-07-02 |
Family
ID=33515111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055887A NO332126B1 (no) | 2003-06-20 | 2005-12-12 | Pyrido[2,1-a]isokinolinderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse i medikamenter samt slike forbindelser for anvendelse i behandling av sykdom |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7122555B2 (he) |
| EP (1) | EP1638970B1 (he) |
| JP (1) | JP4160616B2 (he) |
| KR (1) | KR100730867B1 (he) |
| CN (1) | CN100374439C (he) |
| AR (1) | AR044795A1 (he) |
| AT (1) | ATE489387T1 (he) |
| AU (1) | AU2004251830B8 (he) |
| BR (1) | BRPI0411713B8 (he) |
| CA (1) | CA2529443C (he) |
| CO (1) | CO5640155A2 (he) |
| CR (1) | CR8147A (he) |
| CY (1) | CY1111425T1 (he) |
| DE (1) | DE602004030244D1 (he) |
| DK (1) | DK1638970T3 (he) |
| EA (1) | EA009591B1 (he) |
| EC (1) | ECSP056240A (he) |
| ES (1) | ES2355105T3 (he) |
| HK (1) | HK1093503A1 (he) |
| HR (1) | HRP20110018T1 (he) |
| IL (1) | IL172618A (he) |
| MA (1) | MA27883A1 (he) |
| MX (1) | MXPA05013904A (he) |
| MY (1) | MY140039A (he) |
| NO (1) | NO332126B1 (he) |
| NZ (1) | NZ544221A (he) |
| PL (1) | PL1638970T3 (he) |
| PT (1) | PT1638970E (he) |
| RS (1) | RS52397B (he) |
| SI (1) | SI1638970T1 (he) |
| TN (1) | TNSN05320A1 (he) |
| TW (1) | TWI297011B (he) |
| UA (1) | UA82242C2 (he) |
| WO (1) | WO2005000848A1 (he) |
| ZA (1) | ZA200510298B (he) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0210644A (pt) | 2001-06-27 | 2004-07-20 | Smithkline Beecham Corp | Composto, formulação farmacêutica, método para inibir uma protease que cliva pós prolina/alanina, método para o tratamento ou profilaxia de distúrbios, e, uso do composto |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| EP1608317B1 (en) | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| KR100744893B1 (ko) * | 2003-06-20 | 2007-08-01 | 에프. 호프만-라 로슈 아게 | Ｄｐｐ-ｉｖ 저해제로서 헥사하이드로피리도아이소퀴놀린 |
| WO2005016911A1 (en) | 2003-08-13 | 2005-02-24 | Takeda Pharmaceutical Company Limited | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102127053A (zh) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| EP1753730A1 (en) | 2004-06-04 | 2007-02-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| NZ554943A (en) * | 2004-11-30 | 2010-12-24 | Hoffmann La Roche | Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| ES2477868T3 (es) | 2005-04-22 | 2014-07-18 | Alantos Pharmaceuticals Holding, Inc. | Inhibidores de dipeptidil peptidasa-IV |
| CN101180282B (zh) * | 2005-05-24 | 2011-09-21 | 霍夫曼-拉罗奇有限公司 | （s）-4-氟甲基-二氢-呋喃-2-酮的制备 |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1917001A2 (en) * | 2005-08-11 | 2008-05-07 | F.Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| EP1942898B2 (en) | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| SI1971862T1 (sl) | 2006-04-11 | 2011-02-28 | Arena Pharm Inc | Postopki uporabe GPR119 receptorja za identificiranje spojin, uporabnih za povečanje kostne mase pri posamezniku |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EA200802054A1 (ru) | 2006-04-12 | 2009-04-28 | Пробиодруг Аг | Ингибиторы фермента |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
| WO2007148185A2 (en) * | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| CN101511830B (zh) * | 2006-09-15 | 2013-07-24 | 霍夫曼-拉罗奇有限公司 | 通过烯胺的催化不对称氢化制备吡啶并[2,1-a]异喹啉衍生物的方法 |
| ES2371369T3 (es) * | 2006-09-15 | 2011-12-30 | F. Hoffmann-La Roche Ag | Procedimiento para la preparación de derivados pirido[2,1-a]isoquinolina, que comprende la resolución óptica de una enamina. |
| US7956201B2 (en) | 2006-11-06 | 2011-06-07 | Hoffman-La Roche Inc. | Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| UY31290A1 (es) * | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido | |
| KR101610005B1 (ko) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체 |
| US20090105480A1 (en) * | 2007-08-30 | 2009-04-23 | Ulrike Bromberger | Process for the preparation of a dpp-iv inhibitor |
| US20090163718A1 (en) * | 2007-12-19 | 2009-06-25 | Stefan Abrecht | PROCESS FOR THE PREPARATION OF PYRIDO[2,1-a] ISOQUINOLINE DERIVATIVES |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| EP3626238A1 (en) | 2008-08-15 | 2020-03-25 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
| CA2752437C (en) | 2009-02-13 | 2017-07-11 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
| UY32441A (es) | 2009-02-13 | 2010-09-30 | Boehringer Ingelheim Int | Composicion farmaceutica, metodos de tratamiento y sus usos |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| KR20210033559A (ko) | 2009-11-27 | 2021-03-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
| US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
| US20130023494A1 (en) | 2010-04-06 | 2013-01-24 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| AU2012285904C1 (en) | 2011-07-15 | 2017-08-31 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681956A (en) | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| GB9313913D0 (en) | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
| US5455351A (en) * | 1993-12-13 | 1995-10-03 | Abbott Laboratories | Retroviral protease inhibiting piperazine compounds |
| DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| EP2823812A1 (en) | 1998-02-02 | 2015-01-14 | Trustees Of Tufts College | Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes |
| DE19834591A1 (de) * | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| AU6875800A (en) | 1999-09-10 | 2001-04-17 | Takeda Chemical Industries Ltd. | Heterocyclic compounds and process for the preparation thereof |
| AU1916401A (en) | 1999-11-12 | 2001-06-06 | Guilford Pharmaceuticals Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| WO2001055105A1 (en) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| EP1259246A2 (en) | 2000-02-25 | 2002-11-27 | Novo Nordisk A/S | Use of dpp-iv inhibitors for the treatment of diabetes |
| DK1308439T3 (da) * | 2000-08-10 | 2009-01-12 | Mitsubishi Tanabe Pharma Corp | Prolinderivater og anvendelse af disse som lægemidler |
| WO2002030890A1 (fr) | 2000-10-06 | 2002-04-18 | Tanabe Seiyaku Co., Ltd. | Composes azotes a noyau a cinq elements |
| US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| US6727261B2 (en) * | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
-
2004
- 2004-06-11 AT AT04739841T patent/ATE489387T1/de active
- 2004-06-11 ES ES04739841T patent/ES2355105T3/es not_active Expired - Lifetime
- 2004-06-11 MX MXPA05013904A patent/MXPA05013904A/es active IP Right Grant
- 2004-06-11 BR BRPI0411713A patent/BRPI0411713B8/pt not_active IP Right Cessation
- 2004-06-11 SI SI200431593T patent/SI1638970T1/sl unknown
- 2004-06-11 DK DK04739841.7T patent/DK1638970T3/da active
- 2004-06-11 EA EA200501936A patent/EA009591B1/ru not_active IP Right Cessation
- 2004-06-11 KR KR1020057024424A patent/KR100730867B1/ko active IP Right Grant
- 2004-06-11 NZ NZ544221A patent/NZ544221A/en not_active IP Right Cessation
- 2004-06-11 CA CA2529443A patent/CA2529443C/en not_active Expired - Fee Related
- 2004-06-11 PL PL04739841T patent/PL1638970T3/pl unknown
- 2004-06-11 AU AU2004251830A patent/AU2004251830B8/en not_active Ceased
- 2004-06-11 CN CNB200480017358XA patent/CN100374439C/zh not_active Expired - Fee Related
- 2004-06-11 WO PCT/EP2004/006355 patent/WO2005000848A1/en active Application Filing
- 2004-06-11 DE DE602004030244T patent/DE602004030244D1/de not_active Expired - Lifetime
- 2004-06-11 EP EP04739841A patent/EP1638970B1/en not_active Expired - Lifetime
- 2004-06-11 JP JP2006515913A patent/JP4160616B2/ja not_active Expired - Fee Related
- 2004-06-11 RS YU20050939A patent/RS52397B/en unknown
- 2004-06-11 PT PT04739841T patent/PT1638970E/pt unknown
- 2004-06-16 TW TW093117363A patent/TWI297011B/zh not_active IP Right Cessation
- 2004-06-17 US US10/870,580 patent/US7122555B2/en not_active Expired - Lifetime
- 2004-06-17 AR ARP040102105A patent/AR044795A1/es active IP Right Grant
- 2004-06-18 MY MYPI20042371A patent/MY140039A/en unknown
- 2004-11-06 UA UAA200600527A patent/UA82242C2/uk unknown
-
2005
- 2005-12-12 NO NO20055887A patent/NO332126B1/no not_active IP Right Cessation
- 2005-12-13 CR CR8147A patent/CR8147A/es unknown
- 2005-12-15 MA MA28665A patent/MA27883A1/fr unknown
- 2005-12-15 IL IL172618A patent/IL172618A/he active IP Right Grant
- 2005-12-16 TN TNP2005000320A patent/TNSN05320A1/en unknown
- 2005-12-19 ZA ZA200510298A patent/ZA200510298B/en unknown
- 2005-12-20 CO CO05128097A patent/CO5640155A2/es active IP Right Grant
- 2005-12-20 EC EC2005006240A patent/ECSP056240A/es unknown
-
2007
- 2007-01-10 HK HK07100369A patent/HK1093503A1/xx not_active IP Right Cessation
-
2011
- 2011-01-12 HR HR20110018T patent/HRP20110018T1/hr unknown
- 2011-01-27 CY CY20111100091T patent/CY1111425T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO332126B1 (no) | Pyrido[2,1-a]isokinolinderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse i medikamenter samt slike forbindelser for anvendelse i behandling av sykdom | |
| JP5823476B2 (ja) | Ｎｋ１アンタゴニストとしてのピロリジンおよびピペリジンの誘導体 | |
| JP5669691B2 (ja) | グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター | |
| RU2396257C2 (ru) | Производные 4-аминопиперидина | |
| AU2298699A (en) | N-acyl cyclic amine derivatives | |
| WO2005108359A1 (en) | Novel compounds of proline and morpholine derivatives | |
| EP2522664A1 (en) | Piperidine derivatives as NK1 antagonists | |
| KR920003980B1 (ko) | 축합 디아제핀온의 제조방법 | |
| JP2010090163A (ja) | Ｎｋ１アンタゴニスト | |
| JP2016138122A (ja) | ケモカイン受容体アンタゴニストおよびその使用方法 | |
| KR101268630B1 (ko) | 심혈관 질환 치료용 신규 헤테로사이클일 화합물 | |
| MX2010011985A (es) | Espiro(piperidin-4,2'-pirrolidina)-1-(3,5-trifluorometilfenil)met ilcarboxamidas como antagonistas del receptor de taquicinina nk1. | |
| MXPA00007615A (en) | N-acyl cyclic amine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |